Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.49 |
| ▸ | RRM2 | P31350 | 1/20 | 0.42 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632606 | 0.77 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CRRM2KCNQ3 | |
| SCHEMBL28763189 | 0.76 | P4HTM (0.51) | MAPTLMNAP4HTMCYP11B1CYP11B2 | |
| SCHEMBL29694479 | 0.76 | P4HTM (0.51) | MAPTLMNAP4HTMCYP11B1CYP11B2 | |
| SCHEMBL29694478 | 0.76 | P4HTM (0.51) | MAPTLMNAP4HTMCYP11B1CYP11B2 | |
| SCHEMBL360559 | 0.76 | — | — | |
| SCHEMBL1585755 | 0.75 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CRRM2MAPT | |
| SCHEMBL2487033 | 0.75 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CRRM2MAPT | |
| SCHEMBL4442545 | 0.75 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CRRM2KCNQ3 | |
| SCHEMBL14185017 | 0.75 | KCNQ3 (0.39) | KCNQ3KCNQ2CYP11B1CYP11B2 | |
| SCHEMBL378330 | 0.75 | MAPT (0.48) | ADRA2AADRA2BADRA2CMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2125794-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | Eli Lilly & Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008076705-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | ADRA2A 1310/4885ADRA2B 2271/4885ADRA2C 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.